Skip to main content
Back to Discussions

This implant can restore sight for patients with macular degeneration

Healthcare
Global
Started October 17, 2026

Age-related macular degeneration (AMD) affects more than 5 million people around the world. And until now, no treatment could restore their vision. The Prima system, which was approved in Europe in July and is awaiting FDA clearance in the US, changes that. It combines a retinal implant with camera-­equipped eyeglasses to improve sight in patients…

Source Articles

Add Statement Analysis 0/5
Looking for a particular claim? Search all statements
🗳️ Join the conversation
10 statements to vote on • Your perspective shapes the analysis
📊 Progress to consensus analysis Needs 7+ participants and 20+ votes. Each statement joins once it has 3+ votes.
Participants 0/7
Statements (10+ recommended) 10/10
Total Votes 0/20
💡 Progress updates live here. Analysis can run once all three requirements are met.

Your votes count

No account needed. Your votes are saved and included in the consensus analysis. Create an account to keep a record of your votes.

CLAIM Posted by admin • Oct 17, 2026
Research funding should be allocated to both innovative devices like the Prima system and traditional treatments for macular degeneration.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Oct 17, 2026
The Prima system represents a major step forward in treating previously untreatable eye conditions.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Oct 17, 2026
The Prima system's effectiveness may vary significantly based on individual patient circumstances and conditions.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Oct 17, 2026
The Prima system offers a groundbreaking solution for restoring sight to patients with age-related macular degeneration.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Oct 17, 2026
Access to the Prima system should be expanded to ensure equitable treatment for all patients with macular degeneration.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Oct 17, 2026
The costs associated with the Prima system could create barriers to access for many patients who need it the most.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Oct 17, 2026
The Prima system could lead to a shift in how society views and supports individuals with disabilities related to vision.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Oct 17, 2026
Regulation of medical devices like the Prima system should prioritize patient safety and long-term efficacy over rapid approval.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Oct 17, 2026
Patient education about the Prima system is crucial for informed decision-making regarding their treatment options.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Oct 17, 2026
The Prima system may not be a viable solution for all patients with macular degeneration due to varying degrees of vision loss.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results

💡 How this works

  • • Add statements: Post claims or questions (10 to 500 characters).
  • • Vote: Agree, disagree or unsure on each statement.
  • • Respond: Add detailed arguments for or against, with evidence.
  • • Consensus: Once enough people take part, analysis shows opinion groups and where they agree.

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us